Your browser doesn't support javascript.
loading
Perioperative management of patients on glucagon-like peptide-1 receptor agonists.
Mizubuti, Glenio B; Ho, Anthony M-H; Silva, Leopoldo Muniz da; Phelan, Rachel.
Afiliação
  • Mizubuti GB; Department of Anesthesiology and Perioperative Medicine, Queen's University, Kingston Health Sciences Centre, Kingston, Ontario, Canada.
  • Ho AM; Department of Anesthesiology and Perioperative Medicine, Queen's University, Kingston Health Sciences Centre, Kingston, Ontario, Canada.
  • Silva LMD; Department of Anesthesiology, São Luiz Hospital - Rede D'Or - CMA, Rua Alceu de Campos Rodrigues, São Paulo, SP, Brazil.
  • Phelan R; Department of Anesthesiology and Perioperative Medicine, Queen's University, Kingston Health Sciences Centre, Kingston, Ontario, Canada.
Curr Opin Anaesthesiol ; 37(3): 323-333, 2024 Jun 01.
Article em En | MEDLINE | ID: mdl-38390914
ABSTRACT
PURPOSE OF REVIEW To summarize the mechanism of action, clinical outcomes, and perioperative implications of glucagon-like peptide-1 receptor agonists (GLP-1-RAs). Specifically, this review focuses on the available literature surrounding complications (primarily, bronchoaspiration) and current recommendations, as well as knowledge gaps and future research directions on the perioperative management of GLP-1-RAs. RECENT

FINDINGS:

GLP-1-RAs are known to delay gastric emptying. Accordingly, recent case reports and retrospective observational studies, while anecdotal, suggest that the perioperative use of GLP-1-RAs may increase the risk of bronchoaspiration despite fasting intervals that comply with (and often exceed) current guidelines. As a result, guidelines and safety bulletins have been published by several Anesthesiology Societies.

SUMMARY:

While rapidly emerging evidence suggests that perioperative GLP-1-RAs use is associated with delayed gastric emptying and increased risk of bronchoaspiration (particularly in patients undergoing general anesthesia and/or deep sedation), high-quality studies are needed to provide definitive answers with respect to the safety and duration of preoperative drug cessation, and optimal fasting intervals according to the specific GLP-1-RA agent, the dose/duration of administration, and patient-specific factors. Meanwhile, clinicians must be aware of the potential risks associated with the perioperative use of GLP-1-RAs and follow the recommendations put forth by their respective Anesthesiology Societies.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Assistência Perioperatória / Esvaziamento Gástrico / Agonistas do Receptor do Peptídeo 1 Semelhante ao Glucagon Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Assistência Perioperatória / Esvaziamento Gástrico / Agonistas do Receptor do Peptídeo 1 Semelhante ao Glucagon Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article